热门资讯> 正文
辉瑞、BioNTech赢得欧盟支持更新新冠疫苗
2025-07-25 19:48
- An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorization for Pfizer (NYSE:PFE) and BioNTech’s (NASDAQ:BNTX) COVID-19 shot, updated to target the LP.8.1 variant of the virus.
- The positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) allows the companies to market the monovalent shot for COVID prevention in those aged six months and older in Europe.
- The duo expects to immediately ship the retooled vaccine in all applicable countries, subject to a final decision from the European Commission on the marketing authorization, which is expected “soon,” Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) said.
- The companies added that manufacturing of the LP.8.1-adjusted shot has already begun to ensure there are enough supplies during the upcoming fall and winter season.
More on Pfizer, BioNTech
- Pfizer: Building The Next Oncology Empire
- BioNTech: More Uncertainty Emerges
- Pfizer: Options Activity Speaks Bullish
- Pfizer hit with lawsuits over cancer risk linked to Depo-Provera birth control shot
- Former biotech exec George Tidmarsh to lead key FDA drug center
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
